CN1103533A - 用作抗转移药的具有生物活性的脲基衍生物 - Google Patents

用作抗转移药的具有生物活性的脲基衍生物 Download PDF

Info

Publication number
CN1103533A
CN1103533A CN94190108A CN94190108A CN1103533A CN 1103533 A CN1103533 A CN 1103533A CN 94190108 A CN94190108 A CN 94190108A CN 94190108 A CN94190108 A CN 94190108A CN 1103533 A CN1103533 A CN 1103533A
Authority
CN
China
Prior art keywords
methyl
bis
carbonyl
imino
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94190108A
Other languages
English (en)
Chinese (zh)
Inventor
N·蒙格里
G·比亚索利
M·玛里亚尼
F·索拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmitalia Carlo Erba SL
Original Assignee
Farmitalia Carlo Erba SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SL filed Critical Farmitalia Carlo Erba SL
Publication of CN1103533A publication Critical patent/CN1103533A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN94190108A 1993-03-05 1994-01-31 用作抗转移药的具有生物活性的脲基衍生物 Pending CN1103533A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939304589A GB9304589D0 (en) 1993-03-05 1993-03-05 Biologically active ureido derivatives useful as antimetastic agents
GB9304589.6 1993-03-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN98120766A Division CN1223256A (zh) 1993-03-05 1998-09-28 用作抗转移药的具有生物活性的脲基衍生物

Publications (1)

Publication Number Publication Date
CN1103533A true CN1103533A (zh) 1995-06-07

Family

ID=10731580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94190108A Pending CN1103533A (zh) 1993-03-05 1994-01-31 用作抗转移药的具有生物活性的脲基衍生物

Country Status (17)

Country Link
US (1) US5534539A (OSRAM)
EP (1) EP0639073A1 (OSRAM)
JP (1) JPH07506594A (OSRAM)
KR (1) KR950701217A (OSRAM)
CN (1) CN1103533A (OSRAM)
AU (1) AU669269B2 (OSRAM)
CA (1) CA2134098A1 (OSRAM)
FI (1) FI945164A0 (OSRAM)
GB (1) GB9304589D0 (OSRAM)
HU (1) HUT71400A (OSRAM)
IL (1) IL108665A (OSRAM)
MY (1) MY110004A (OSRAM)
NZ (1) NZ261308A (OSRAM)
PL (1) PL305981A1 (OSRAM)
TW (1) TW262465B (OSRAM)
WO (1) WO1994020095A1 (OSRAM)
ZA (1) ZA941126B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107235866A (zh) * 2017-06-13 2017-10-10 重庆医科大学 一种用于检测次磺酸化蛋白质的荧光探针、制备方法及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
GB9504065D0 (en) * 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
GB9602721D0 (en) * 1996-02-09 1996-04-10 Pharmacia Spa Biologically active ureido derivatives useful in the treatment of multiple sclerosis
WO1999027939A1 (en) 1997-12-04 1999-06-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
WO1999058126A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
ATE435202T1 (de) * 2002-01-11 2009-07-15 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
EP3381897A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5012285A (en) * 1984-10-12 1986-05-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
CA1308516C (en) * 1987-07-06 1992-10-06 J. William Lown Oligopeptide anticancer and antiviral agents
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
GB9024738D0 (en) * 1990-11-14 1991-01-02 Erba Carlo Spa A new method of treatment of tumor necroisis factor(tnf)-related diseases
GB9116896D0 (en) * 1991-08-06 1991-09-18 Erba Carlo Spa 3-deoxymannosamine derivatives and process for their preparation
GB9216962D0 (en) * 1992-08-11 1992-09-23 Erba Carlo Spa Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107235866A (zh) * 2017-06-13 2017-10-10 重庆医科大学 一种用于检测次磺酸化蛋白质的荧光探针、制备方法及其应用
WO2018228079A1 (zh) * 2017-06-13 2018-12-20 重庆医科大学 一种用于检测次磺酸化蛋白质的荧光探针、制备方法及其应用
US11209362B2 (en) 2017-06-13 2021-12-28 Chongqing Medical University Fluorescent probe for detecting sulfenylated protein, preparation method thereof, and application thereof

Also Published As

Publication number Publication date
TW262465B (OSRAM) 1995-11-11
PL305981A1 (en) 1995-02-20
GB9304589D0 (en) 1993-04-21
IL108665A (en) 1997-03-18
ZA941126B (en) 1994-08-30
US5534539A (en) 1996-07-09
AU669269B2 (en) 1996-05-30
JPH07506594A (ja) 1995-07-20
EP0639073A1 (en) 1995-02-22
IL108665A0 (en) 1994-05-30
MY110004A (en) 1997-11-29
AU6000394A (en) 1994-09-26
FI945164A7 (fi) 1994-11-02
HUT71400A (en) 1995-11-28
FI945164A0 (fi) 1994-11-02
NZ261308A (en) 1996-02-27
KR950701217A (ko) 1995-03-23
CA2134098A1 (en) 1994-09-15
WO1994020095A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
CN1738605A (zh) 改变药物晶体形成的方法
CN1026984C (zh) 偏端霉素衍生物的制备方法
CN101048376A (zh) 二氢吲哚化合物及其生产方法
CN1738614A (zh) 包含(－)－3－(3,4－二甲氧基－苯基)－3－(1－氧代－1,3－二氢－异吲哚－2－基)－丙酰胺的组合物及其使用方法
CN1671693A (zh) 吲哚满酮衍生物的制备方法
CN1118164A (zh) 亚吡咯基甲基衍生物及其制备方法
CN1399633A (zh) 嘧啶衍生物
CN1305465A (zh) 芳基链烷酰基哒嗪化合物
CN1103533A (zh) 用作抗转移药的具有生物活性的脲基衍生物
CN1147297C (zh) 新型七叶亭衍生物及医药组合物
CN1683373A (zh) 噻吩并吡啶取代的乙酰肼衍生物
CN1942437A (zh) 作为环氧化酶－1－环氧化酶－2抑制剂的取代氮杂环丁烷化合物及其制备方法和作为药物的用途
CN101028260A (zh) 取代的异穿心莲内酯衍生物的用途
CN1166623C (zh) 2-苯氧基苯胺类衍生物
CN86103227A (zh) 制备2-吡咯烷酮衍生物的方法
CN88103735A (zh) 新的吡唑啉衍生物及以该化合物为活性成份治疗脑血管疾病的药物
CN1255387C (zh) 可用作选择性cox－2抑制剂的嘧啶衍生物
CN1228330C (zh) 咪唑衍生物或它们的盐
CN101039921A (zh) 3－[5－氯－4－[(2,4－二氟苄基)氧基]－6－氧代嘧啶－1(6h)－基]－n－(2－羟乙基)－4－甲基苯甲酰胺的晶形
CN1738613A (zh) 包含(+)－3－(3,4－二甲氧基－苯基)－3－(1－氧代－1,3－二氢－异吲哚－2－基)－丙酰胺的组合物及其使用方法
CN1446225A (zh) 5′－脱氧－n－(取代氧羰基)－5－氟胞嘧啶及其衍生物、制备方法,和包括该物质作为活性成分的抗癌组合物
CN1094126C (zh) 吡咯并吖庚因化合物
CN1176654C (zh) 喹啉酮衍生物制剂及其制法
CN1223256A (zh) 用作抗转移药的具有生物活性的脲基衍生物
CN1422272A (zh) 吡咯并哒嗪衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: The Upjohn Co.

Applicant before: Farmitalia Carlo Erba s.r.l.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: FARMITALIA CARLO ERBA S.R.L. TO: PHARMACIA + UPJOHN S.P.A.

C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication